Literature DB >> 16259751

Drug delivery to tumours: recent strategies.

L Harivardhan Reddy1.   

Abstract

Despite several advancements in chemotherapy, the real therapy of cancer still remains a challenge. The development of new anti-cancer drugs for the treatment of cancer has not kept pace with the progress in cancer therapy, because of the nonspecific drug distribution resulting in low tumour concentrations and systemic toxicity. The main hindrance for the distribution of anti-cancer agents to the tumour site is the highly disorganized tumour vasculature, high blood viscosity in the tumour, and high interstitial pressure within the tumour tissue. Recently, several approaches such as drug modifications and development of new carrier systems for anti-cancer agents have been attempted to enhance their tumour reach. Approaches such as drug delivery through enhanced permeability and retention (EPR) effect have resulted in a significant improvement in concentration in tumours, while approaches such as drug-carrier implants and microparticles have resulted in improvement in local chemotherapy of cancer. This review discusses different strategies employed for the delivery of anti-cancer agents to tumours, such as through EPR effect, local chemotherapeutic approaches using drug delivery systems, and special strategies such as receptor-mediated delivery, pH-based carriers, application of ultrasound and delivery to resistant tumour cells and brain using nanoparticles.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16259751     DOI: 10.1211/jpp.57.10.0001

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  28 in total

1.  Nanostructured Surfaces to Target and Kill Circulating Tumor Cells While Repelling Leukocytes.

Authors:  Michael J Mitchell; Carlos A Castellanos; Michael R King
Journal:  J Nanomater       Date:  2012       Impact factor: 2.986

2.  Mucoadhesive fenretinide patches for site-specific chemoprevention of oral cancer: enhancement of oral mucosal permeation of fenretinide by coincorporation of propylene glycol and menthol.

Authors:  Xiao Wu; Kashappa-Goud H Desai; Susan R Mallery; Andrew S Holpuch; Maynard P Phelps; Steven P Schwendeman
Journal:  Mol Pharm       Date:  2012-03-06       Impact factor: 4.939

3.  Over-pressure suppresses ultrasonic-induced drug uptake.

Authors:  S Briant Stringham; Maria A Viskovska; Eric S Richardson; Seiga Ohmine; Ghaleb A Husseini; Byron K Murray; William G Pitt
Journal:  Ultrasound Med Biol       Date:  2008-12-04       Impact factor: 2.998

Review 4.  Targeted delivery with peptidomimetic conjugated self-assembled nanoparticles.

Authors:  Esmaiel Jabbari
Journal:  Pharm Res       Date:  2008-12-17       Impact factor: 4.200

5.  Exploiting lipid raft transport with membrane targeted nanoparticles: a strategy for cytosolic drug delivery.

Authors:  Kathryn C Partlow; Gregory M Lanza; Samuel A Wickline
Journal:  Biomaterials       Date:  2008-05-16       Impact factor: 12.479

6.  E-selectin liposomal and nanotube-targeted delivery of doxorubicin to circulating tumor cells.

Authors:  Michael J Mitchell; Christina S Chen; Varun Ponmudi; Andrew D Hughes; Michael R King
Journal:  J Control Release       Date:  2012-03-01       Impact factor: 9.776

7.  Development and in vitro-in vivo evaluation of fenretinide-loaded oral mucoadhesive patches for site-specific chemoprevention of oral cancer.

Authors:  Kashappa-Goud H Desai; Susan R Mallery; Andrew S Holpuch; Steven P Schwendeman
Journal:  Pharm Res       Date:  2011-06-15       Impact factor: 4.200

8.  Tuning the Size of Poly(lactic-co-glycolic Acid) (PLGA) Nanoparticles Fabricated by Nanoprecipitation.

Authors:  Wei Huang; Chenming Zhang
Journal:  Biotechnol J       Date:  2017-10-13       Impact factor: 4.677

9.  Near-infrared-resonant gold/gold sulfide nanoparticles as a photothermal cancer therapeutic agent.

Authors:  André M Gobin; Emily M Watkins; Elizabeth Quevedo; Vicki L Colvin; Jennifer L West
Journal:  Small       Date:  2010-03-22       Impact factor: 13.281

10.  Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model.

Authors:  C-S Chen; Y Jounaidi; T Su; D J Waxman
Journal:  Cancer Gene Ther       Date:  2007-09-14       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.